We have an updated report [Version - 2023] available. Kindly sign up to get the sample of the report.

MEA Cancer Screening Market (2019-2027)

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Middle East and Africa cancer screening market

The Middle East and Africa (MEA) cancer screening market is growing at a very slow rate. The MEA market is projected to reach USD 50.61 Bn by 2023, at a compound annual growth rate (CAGR) of 11.5% during the forecast period (2018-2023).The United Arab Emirates (UAE), Saudi Arabia and Kuwait are expected to drive the MEA cancer screening market while Africa will witness a moderate growth. Due to limited availability, the MEA occupies the least share in the market.

By end users, the market is segmented into hospitals, laboratories and independent physicians and clinics. Independent physicians and clinics along with hospitals will witness an optimistic growth during the forecast period 2018-2023.
By screening type, the market is segmented into laboratory, genetic, imaging, biopsy and endoscopy tests. Laboratory, biopsy and genetic tests will be the leading segments during the forecast period 2018-2023.
By application type, the market can be segmented into lung, breast, melanoma, kidney and colorectal cancer types. Lung, melanoma and breast cancer will occupy a larger share of the market during the forecast period 2018-2023.
By countries, the market is divided into UAE, Saudi Arabia and the rest of the MEA.

Key growth factors

The rising prevalence of target disorders, an aging population, and the presence of favourable government initiatives for early disease diagnosis. There is increased support from the government in the form of awareness campaigns and performance-based reimbursements to contribute towards the growth of the cancer screening market.
Threats and key players
The region suffers from an imbalance in its socio-economic and political scenario which makes the services inaccessible. An informal and fragmented system will act as a major hurdle for the market while catering to the rising incidence of cancer cases.
Key players in the MEA cancer screening market are Thermo Fisher Scientific, GE Healthcare, Siemens Healthcare, Roche Diagnostics and Illumina Inc.

What is covered in the report?

1. Overview of the MEA cancer screening market.
2. Market drivers and challenges in the MEA cancer screening market.
3. Market trends in the MEA cancer screening market.
4. Historical, current and forecasted market size data for MEA market segmentation based on type of end users (hospitals, laboratories, independent physicians and clinics) - by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) -by application (lung, breast, melanoma, kidney and colorectal).
5. Historical, current and forecasted market size data for the MEA market segmentation based on type of end-user (hospitals, laboratory, independent physicians and clinics) - by type of screening (laboratory, genetic, imaging, biopsy and endoscopy) -by type of application (lung, breast, melanoma, kidney and colorectal).
6. Historical, current and forecasted market size data of the cancer screening market by countries and others (other parts of MEA) - by revenue.
7. Historical, current and forecasted market size data for country-wise segments - by revenue.
8. Analysis of the competitive landscape and profiles of major competitors operating in the MEA market.

Why buy?

o Understand the demand for cancer screening market to determine the viability of the market.
o Understand the country-specific market size and observations for each segment.
o Develop strategies based on the drivers, trends and highlights for each of the segments.
o Evaluate the value chain to determine the workflow and to get an idea of the current position where you are placed.
o Recognize the key competitors of this market and respond accordingly.
o Identify the initiatives and growth strategies taken by the major companies and decide the direction of further growth.
o Define the competitive positioning by comparing the products and services compared with the key players in the market.

Customizations available

With the given market data, Netscribes offers customizations according to specific needs. Write to us at support@researchonglobalmarkets.com.

Chapter 1: Executive summary

1.1 Market scope and segmentation
1.2 Key questions answered in this study
1.3 Executive summary

Chapter 2: The Middle East and Africa cancer screening market - market overview

2.1. The MEA market overview - market trends, market attractiveness analysis, country-wise market revenue (USD)
2.2. The MEA - market drivers and challenges
2.3. Value chain analysis - cancer screening market
2.4. Porter's five forces analysis
2.5. Market segmentation based on type of end users (hospitals, laboratories independent physicians and clinics)
2.5. a. Hospitals - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. b. Laboratory - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. c. Independent physicians and clinics revenue - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.5. d. Growth drivers and key challenges
2.6. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
2.6. a. Laboratory - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. b. Genetic - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. c. Imaging - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. d. Biopsy - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. e. Endoscopy - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.6. f. Growth drivers and key challenges
2.7. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
2.7. a. Lung - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. b. Breast - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. c. Melanoma - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. d. Kidney - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. e. Colorectal - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
2.7. f. Growth drivers and key challenges
2.8. Major country penetration

Chapter 3. The UAE cancer screening market

3.1. The UAE market overview - market trends, market attractiveness analysis, country-wise market revenue (USD)
3.2. Market segmentation based on type of end users (hospitals, laboratories independent physicians and clinics)
3.2. a. Hospitals - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. b. Laboratory - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. c. Independent physicians and clinics revenue - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.2. d. Growth drivers and key challenges
3.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
3.3. a. Laboratory - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. b. Genetic - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. c. Imaging - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. d. Biopsy - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. e. Endoscopy - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.3. f. Growth drivers and key challenges
3.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
3.4. a. Lung - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. b. Breast - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. c. Melanoma - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. d. Kidney - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. e. Colorectal - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
3.4. f. Growth drivers and key challenges

Chapter 4. Saudi Arabia cancer screening market

4.1. Saudi Arabia market overview - market trends, market attractiveness analysis, country-wise market revenue (USD)
4.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
4.2. a. Hospitals - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. b. Laboratory - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. c. Independent physicians and clinics revenue - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.2. d. Growth drivers and key challenges
4.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
4.3. a. Laboratory - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. b. Genetic - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. c. Imaging - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. d. Biopsy - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. e. Endoscopy - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.3. f. Growth drivers and key challenges
4.4. Market segmentation based on type of application type (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
4.4. a. Lung - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. b. Breast - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. c. Melanoma - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. d. Kidney - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. e. Colorectal - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
4.4. f. Growth drivers and key challenges

Chapter 5. Others (the rest of MEA) cancer screening market

5.1. Others (the rest of MEA) market overview - market trends, market attractiveness analysis, country-wise market revenue (USD)
5.2. Market segmentation based on type of end users (hospitals, laboratory, independent physicians and clinics)
5.2. a. Hospitals - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. b. Laboratory - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. c. Independent physicians and clinics revenue - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.2. d. Growth drivers and key challenges
5.3. Market segmentation based on type of screening (laboratory, genetic, imaging, biopsy and endoscopy) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
5.3. a. Laboratory - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. b. Genetic - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. c. Imaging - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. d. Biopsy - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. e. Endoscopy - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.3. f. Growth drivers and key challenges
5.4. Market segmentation based on type of application (lung, breast, melanoma, kidney and colorectal) Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn).
5.4. a. Lung - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. b. Breast - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. c. Melanoma - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. d. Kidney - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. e. Colorectal - Historical (2015-2017) and forecasted (2018-2023) market size (USD Bn), key observations
5.4. f. Growth drivers and key challenges

Chapter 6: Competitive landscape

6.1. Thermo Fisher Scientific
6.1. a. Company snapshot
6.1. b. Product offerings
6.1. c. Growth strategies
6.1. d. Initiatives
6.1. e. Geographical presence
6.1. f. Key numbers
6.2. Siemens Healthineers
6.2. a. Company snapshot
6.2. b. Product offerings
6.2. c. Growth strategies
6.2. d. Initiatives
6.2. e. Geographical presence
6.2. f. Key numbers
6.3. GE Healthcare
6.3. a. Company snapshot
6.3. b. Product offerings
6.3. c. Growth strategies
6.3. d. Initiatives
6.3. e. Geographical presence
6.3. f. Key numbers
6.4. Roche Diagnostics
6.4. a. Company snapshot
6.4. b. Product offerings
6.4. c. Growth strategies
6.4. d. Initiatives
6.4. e. Geographical presence
6.4. f. Key numbers
6.5. Illumina Inc.
6.5. a. Company snapshot
6.5. b. Product offerings
6.5. c. Growth strategies
6.5. d. Initiatives
6.5. e. Geographical presence
6.5. f. Key numbers

Chapter 7: Conclusion

Chapter 8: Appendix

8.1. List of tables
8.2. Assumptions
8.3. Research and methodology
8.4. About Netscribes Inc.

Note: The Table of Contents (Toc) provided above contains the targeted coverage. The coverage is subject to change as we progress with the research.
Disclaimer: The report will be delivered within 5-7 business days post payment confirmation

Choose License Type

Happy To Assist You

Contact Images

We will be happy to help you find what you need. Please call us or write to us:

Frequently Asked Questions

This report incorporates the analysis of factors that augments the market growth. Report presents competitive landscape of the global market. This also provides the scope of different segments and applications that can potentially influence the market in the future. The analysis is based on current market trends and historic growth data. It includes detailed market segmentation, regional analysis, and competitive landscape of the industry.
The report efficiently evaluates the current market size and provides industry forecast. The market was valued at xxx Million US$ in 2019, and is expected to grow at a CAGR of xx% during the period 2020-2027.
The report efficiently evaluates the current market size and provides forecast for the industry in terms of Value (US$ Mn) and Volume (Thousands Units).
Market is segmented by:
  • Product Types
  • Drug Class
  • Indication
  • Applications
  • Services Types
  • End-users
  • Distribution channel
  • Regions
The report share key insights on the following:
  • Current market size
  • Market forecast
  • Market opportunities
  • Key drivers
  • Restraints
  • Pipeline Analysis
  • Incidence Rate
  • Epidemiology Analysis
  • Prevalence rate
  • Regulatory scenario
  • Industry trend
  • Pestle Analysis
  • Porter’s Analysis
  • New product approvals/launch
  • Promotion and marketing initiatives
  • Pricing analysis
  • Export-import analysis
  • Trade analysis
  • Competitive landscape
It helps the businesses in making investments decisions.
Customization helps the organization to gain insight on specific segments and regions of interest. Thus, WMR offers tailored report information based on business requirement in order to take strategic calls.
Contact us

mapicon
Sales Office (U.S.):
Worldwide Market Reports, 533 Airport Boulevard, Suite 400, Burlingame, CA 94010, United States

mapicon+1-415-871-0703

mapicon
Asia Pacific Intelligence Center (India):
Worldwide Market Reports, 403, 4th Floor, Bremen Business Center, Aundh, Pune, Maharashtra 411007, India.

Newsletter

Want us to send you latest updates of the current trends, insights, and more, signup to our newsletter (for alerts, special offers, and discounts).


Secure Payment By:
paymenticon

This website is secured Origin CA certificate on the server, Comodo, Firewall and Verified Sitelock Malware Protection

secureimg

© 2024 Worldwide Market Reports. All Rights Reserved